[Possible Radiation Dose Reduction in Abdominal Plain CT Using Deep Learning Reconstruction].

Purpose: The purposes of this study were to evaluate the low-contrast detectability of CT images assuming hepatocellular carcinoma and to determine whether dose reduction in abdominal plain CT imaging is possible.

Methods: A Catphan 600 was imaged at 350, 250, 150, and 50 mA using an Aquilion ONE PRISM Edition (Canon) and reconstructed using deep learning reconstruction (DLR) and model-based iterative reconstruction (MBIR). A low-contrast object-specific contrast-to-noise ratio (CNR) was measured and compared in a 5-mm module with a CT value difference of 10 HU, assuming hepatocellular carcinoma; a visual examination was also performed.

Impact of a new deep-learning-based reconstruction algorithm on image quality in ultra-high-resolution CT: clinical observational and phantom studies.

Objectives: To demonstrate the effect of an improved deep learning-based reconstruction (DLR) algorithm on Ultra-High-Resolution Computed Tomography (U-HRCT) scanners.

Methods: Clinical and phantom studies were conducted. Thirty patients who underwent contrast-enhanced CT examination during the follow-up period were enrolled.

Angular accuracy of plain radiographic measurements in leg alignment: Teleoroentgenogram versus orthoroentgenogram.

Background: The purpose of the present study was to evaluate the accuracy of the measurements associated with leg alignment on a teleoroentgenogram and an orthoroentgenogram.

Methods: The models being irradiated were manufactured and represented 10° varus and 15° varus leg alignment, in which the true values of hip-knee-ankle angle (HKAA), mechanical axis (MA) length, and percentage of MA (%MA) were already known. HKAA, MA length, and %MA were measured in various radiographic conditions of the teleoroentgenogram and orthoroentgenogram.

Efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with multiple sclerosis: Interim analysis of the randomized placebo-controlled study.

Background: The use of dimethyl fumarate has not been reported in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis.

Objectives: The purpose of this study was to evaluate the efficacy and safety of dimethyl fumarate in treatment-naïve Japanese patients with relapsing-remitting multiple sclerosis.

Methods: APEX was a phase 3, multinational trial, which consisted of a 24-week, randomized (1:1), double-blind study where patients received dimethyl fumarate 240 mg or placebo twice daily, followed by an open-label extension where all patients received dimethyl fumarate 240 mg.

[Improvement of Image Quality in the Axial Section Using High-resolution Scan Mode and Hybrid Iterative Reconstruction in Ultra-high-resolution Computed Tomography].

The purpose of this study is to compare the physical characteristics and visibility of high-resolution and conventional images acquired with the same X-ray dose, and to investigate the superiority of super high-resolution imaging. A Catphan phantom was scanned in the normal resolution (NR), high-resolution (HR), and super high-resolution (SHR) modes of ultra-high-resolution computed tomography at 120 kV and 75 mAs. All images were reconstructed into a 5-mm thick image slices with filtered back-projection (FBP) and hybrid image reconstruction (HIR), which included normal and enhanced adaptive iterative dose reduction 3D (AIDR and eAIDR, respectively).

72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.

Introduction: The long-term safety of dimethyl fumarate (DMF) in patients with relapsing-remitting multiple sclerosis (RRMS) has been studied in mainly Caucasian patients. The present interim analysis aimed to evaluate the 72-week safety of DMF in Japanese patients with RRMS.

Methods: Safety data of Japanese subjects enrolled in the 24-week randomised, double-blind, placebo-controlled APEX study (Part I) and its following open-label extension (Part II) were analysed at 72 weeks from the beginning of Part I.